Study and Treatment of Post Lyme Disease (STOP-LD)

NCT ID: NCT00000937

Last Updated: 2010-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2005-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see how well antibiotics work in reducing chronic fatigue symptoms, such as tiredness, in patients that were treated for Lyme Disease. Fatigue is a common symptom of Lyme Disease. When fatigue does not improve after treatment, patients are considered to have Post Lyme Syndrome (PLS). The chronic fatigue seen in these patients appears to be related to the initial infection which causes Lyme Disease. It is believed, but not proven, that treatment with antibiotics may be effective in relieving chronic fatigue in PLS patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

You will be assigned randomly (like tossing a coin) to receive either antibiotics or a placebo (sugar pill). Neither you nor your doctor will know which you are receiving. You will learn to give yourself the injection, and you will remain on your study drug for 28 days. A home health care nurse will visit you twice a week to check the injection site, and at weeks 1 and 3 the nurse will draw blood for laboratory tests. At months 1 and 6, you will be examined to see if you have fewer chronic fatigue symptoms after the antibiotics. This will include a fatigue questionnaire, a test of your mental processing speed, and a test of your cerebrospinal fluid.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lyme Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antibiotics

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

You may be eligible for this study if you:

* Are between 18 and 65 years of age.
* Are a resident of Long Island or greater NY metropolitan area.
* Are fluent in English.
* Have a history of Lyme Disease.
* Have completed antibiotic treatment for Lyme Disease 6 or more months before starting the study.
* Have severe fatigue.
* Are not pregnant or planning to be pregnant.

Exclusion Criteria

You will not be eligible for this study if you:

* Have or have had major medical, neurologic, or psychiatric disorder.
* Have had prior chronic pain, fatigue, or recurrent severe headaches before the onset of Lyme Disease.
* Have had Fibromyalgia Syndrome.
* Have a history of sleep apnea, narcolepsy, or other serious sleep disorder.
* Have a learning disability.
* Have had head trauma requiring hospitalization.
* Have symptomatic gallbladder disease.
* Are anemic.
* Abuse alcohol or illicit drugs.
* Have been treated with another antimicrobial agent for Lyme Disease within 6 months of study.
* Need to be receiving systemic steroid therapy during drug administration and follow-up.
* Have used benzodiazepines within 1 month of study entry.
* Are allergic to Beta lactams (a class of antibiotics).
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lauren Krupp

Stony Brook, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AI031561-04A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DMID 96-182

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tetracycline Treatment Tolerability Trial
NCT05219929 ENROLLING_BY_INVITATION PHASE2
Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402 RECRUITING PHASE1/PHASE2
Phase 1/2 Lyme Vaccine Study
NCT01504347 COMPLETED PHASE1/PHASE2
Borrelia B-cell Diagnostics
NCT06045416 RECRUITING